On May 13, 2013 Sorrento Therapeutics reported the acquisition of exclusive distribution rights from Samyang Biopharmaceuticals to Cynviloq (marketed as Genexol-PM in South Korea) in the 27 countries of European Union (EU) (Press release Sorrento Therapeutics, MAY 13, 2013, View Source [SID:1234500326]). IGDRASOL had previously obtained the exclusive U.S. distribution rights to Cynviloq from Samyang. STI has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!